Compare WMK & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | DNTH |
|---|---|---|
| Founded | 1912 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1994 | 2018 |
| Metric | WMK | DNTH |
|---|---|---|
| Price | $62.25 | $85.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $119.60 |
| AVG Volume (30 Days) | 127.7K | ★ 810.8K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 5.96 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $4,714,573,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $58.85 |
| P/E Ratio | $24.70 | ★ N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $61.27 | $13.37 |
| 52 Week High | $90.23 | $86.75 |
| Indicator | WMK | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 83.74 |
| Support Level | N/A | $33.94 |
| Resistance Level | $68.14 | N/A |
| Average True Range (ATR) | 2.29 | 4.43 |
| MACD | -1.04 | 3.44 |
| Stochastic Oscillator | 6.14 | 92.50 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.